fingolimod hydrochloride has been researched along with Dyspnea in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Azimi, AR; Nourbakhsh, B; Safavi, F | 1 |
| Andelova, M; Derfuss, T; Kappos, L; Lindberg, RL; Naegelin, Y; Rasenack, M; Rychen, J; Sprenger, T; Stippich, C | 1 |
| Bianco, A; De Fino, C; Lucchini, M; Mirabella, M; Nociti, V; Patanella, AK; Rossini, PM; Savio, FL | 1 |
3 other study(ies) available for fingolimod hydrochloride and Dyspnea
| Article | Year |
|---|---|
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Topics: Adult; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Disease Susceptibility; Dyspnea; Epidemics; Female; Fever; Fingolimod Hydrochloride; Glatiramer Acetate; Hospitalization; Humans; Hydroxybutyrates; Immunocompromised Host; Immunologic Factors; Intensive Care Units; Interferons; Iran; Lung; Lymphocyte Depletion; Male; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severity of Illness Index; Toluidines; Tomography, X-Ray Computed | 2020 |
Efficacy and Safety of Fingolimod in an Unselected Patient Population.
Topics: Adult; Aged; Case-Control Studies; Cytokines; Dyspnea; Edema; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies | 2016 |
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
Topics: Adult; Dyspnea; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lung; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2016 |